Trial Profile
A Phase 1, Multiple-Dose, Open-Label Study to Determine and Compare Plasma and Intrapulmonary Pharmacokinetics of WCK 2349 in Healthy Adult Human Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Jan 2018
Price :
$35
*
At a glance
- Drugs Alalevonadifloxacin (Primary)
- Indications Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
- Focus Pharmacokinetics
- Sponsors Wockhardt
- 20 Dec 2017 Results published in the Antimicrobial Agents and Chemotherapy
- 12 Apr 2016 Results presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
- 28 Oct 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.